Mateon enters into merger agreement with Oncotelic
Mateon and Oncotelic announced they have entered into a definitive agreement with respect to a merger, creating a publicly traded immuno-oncology company with a robust pipeline of first in class TGF-β immunotherapies for late stage cancers such as gliomas, pancreatic cancer and melanoma. April 18, 2019